SCHEMBL1803273

SCHEMBL1803273

COC(=O)c1ccc(CN2C(=O)CNC23CCN(C(=O)c2ccc(C(C)(C)C)cc2)CC3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
HPGD P15428 4/20 0.44
ALOX15 P16050 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ALDH1A1 P00352 5/20 0.42
HTT P42858 3/20 0.42
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1L1 Q9UHC9 2/20 0.42
CYP2D6 P10635 1/20 0.42
TSHR P16473 1/20 0.42
CRBN Q96SW2 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151551 0.90 MEN1 (0.51) MEN1KMT2AHPGDALOX15ALDH1A1
SCHEMBL1801517 0.83 ALDH1A1 (0.43) MEN1KMT2AOPRD1OPRK1ALDH1A1
SCHEMBL1801939 0.83 OPRD1 (0.47) OPRD1OPRK1HTTCYP2D6TSHR
SCHEMBL1801345 0.81 MEN1 (0.45) MEN1KMT2AOPRD1OPRK1ALDH1A1
SCHEMBL1797571 0.80 LMNA (0.44) MEN1KMT2AHTTKDM4ETSHR
SCHEMBL1803525 0.80 NPC1 (0.44) MEN1KMT2AOPRD1OPRK1ALDH1A1
SCHEMBL1799853 0.79 OPRD1 (0.46) MEN1KMT2AOPRD1OPRK1ALDH1A1
SCHEMBL1803371 0.79 OPRD1 (0.40) MEN1KMT2AOPRD1OPRK1ALDH1A1
SCHEMBL3920891 0.79 LMNA (0.44) MEN1KMT2AALDH1A1HTTKDM4E
SCHEMBL12326127 0.79 NPC1 (0.47) MEN1KMT2AALDH1A1HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 MEN1 1474/4885KMT2A 4267/4885OPRD1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.